| P50 | author | Caroline Perner | Q61479434 |
| P2093 | author name string | B Schraven | |
| | T Fischer | |
| | C Ebert | |
| | F H Heidel | |
| | B Isermann | |
| | S Ranjan | |
| | S Frey | |
| | D Wolleschak | |
| | C Fahldieck | |
| | T M Schnöder | |
| | M C Pils | |
| | A Polanetzki | |
| | U Schönborn | |
| P2860 | cites work | Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 |
| | JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 |
| | Ruxolitinib versus standard therapy for the treatment of polycythemia vera. | Q33420037 |
| | An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor | Q34343220 |
| | Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. | Q34434935 |
| | Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor | Q35552421 |
| | Cytokine signaling modules in inflammatory responses | Q37133450 |
| | Epo-induced erythroid maturation is dependent on Plcγ1 signaling. | Q40386692 |
| | JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms | Q41138516 |
| | Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. | Q42609684 |
| | Bilateral toxoplasmosis retinitis associated with ruxolitinib | Q44909357 |
| | Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. | Q45350105 |
| | Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 |
| P433 | issue | 4 | |
| P304 | page(s) | 991-995 | |
| P577 | publication date | 2015-08-05 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function | |
| P478 | volume | 30 | |